Description:
Baloxavir marboxil is a first-in-class, one-dose oral medicine with a novel proposed mechanism of action that has demonstrated efficacy in a wide range of influenza viruses, including in vitro activity against oseltamivir-resistant strains and avian strains (H7N9, H5N1) in non-clinical studies. Baloxavir is a polymerase acidic, cap-dependent, endonuclease inhibitor that is indicated for the treatment of acute uncomplicated influenza in patients aged 12 years and older who have been symptomatic for no more than 48 hours. It blocks viral proliferation by binding to one of two endonuclease binding sites, inhibiting the initiation of mRNA synthesis for both influenza A and influenza B strains. Baloxavir can interact with polyvalent cation-containing products, which can decrease its plasma concentration.
- Molecular Weight: 483.49
- Molecular Formula: C24H19F2N3O4S
Purity: ≥98%
Canonical SMILES:
C1COCC2N1C(=O)C3=C(C(=O)C=CN3N2C4C5=C(CSC6=CC=CC=C46)C(=C(C=C5)F)F)O
InChI:
InChI=1S/C24H19F2N3O4S/c25-16-6-5-13-15(20(16)26)12-34-18-4-2-1-3-14(18)21(13)29-19-11-33-10-9-27(19)24(32)22-23(31)17(30)7-8-28(22)29/h1-8,19,21,31H,9-12H2/t19-,21+/m1/s1
InChIKey: FIDLLEYNNRGVFR-CTNGQTDRSA-N
- Boiling Point: 644.7±65.0 °C at 760 mmHg
- Solubility: Soluble in DMSO.
- Appearance: Solid Powder
- Storage: Powder: -20°C 3 years4°C 2 yearsIn solvent: -80°C 6 months-20°C 1 months
Synonyms:
Baloxavir acid; BXA; Xofluza; S-033447
More details are to be found on supplier website
